The Gray Area in Genetic Testing Becomes Clearer: Decoding 6718 PALB2 Variants
In this article
By determining the cancer risk associated with thousands of variants of uncertain significance (VUS) in the PALB2 gene, researchers have opened the door to a new era in genetic counseling.
This large-scale study published in Nature Communications aimed to eliminate this genetic uncertainty by individually producing 6718 different PALB2 variants in the laboratory and testing their functions.
Study Design: Molecular Detective Work
This is one of the most comprehensive functional screening studies ever conducted. Researchers focused on regions of the PALB2 gene critical to protein function: the coiled-coil (CC) and WD40 domains. These regions enable interactions with the BRCA1 and BRCA2 proteins essential for DNA repair.
Building a Library (Site-Saturation Mutagenesis)
Each amino acid in the target regions of the PALB2 gene was individually replaced with every other possible amino acid. This created a vast mutant gene library covering, across 11 exons, 84% of all possible missense variants.
The Cellular Test Environment
Mouse embryonic stem cells (mES) with their own PALB2 gene deleted (knocked out) were used. Laboratory-produced mutant PALB2 genes were individually integrated into these cells.
The Survival Test (PARP Inhibitor)
The cells were treated with a PARP inhibitor (olaparib). Cells with defective PALB2 normally die with this drug. If the transferred variant was functional, the cell resisted the drug and survived; if the variant was defective, the cell died.
Validation and Clinical Comparison
The findings were not confined to mouse cells. In human haploid cells (HAP1), they were validated using saturation genome editing (SGE) . The resulting data were also compared with large human genome databases such as gnomAD, FLOSSIES and BRAVO, and with case-control studies involving 485000 cases (BRIDGES, CARRIERS, CZECANCA).
Results: The Report Card for 6718 Variants
Researchers divided each variant into three classes according to cell survival scores (depletion scores). This classification determined the status of 872 variants that had remained uncertain in the ClinVar database for years.
How Much Does Breast Cancer Risk Increase?
The most striking aspect of the study was the comparison of missense variants identified as damaging in the laboratory with real patient data. The findings showed risk levels similar to those of mutations that completely disrupt the protein's structure (truncating mutations).
| Variant Type | Breast Cancer Risk (Odds Ratio) | Clinical Meaning |
|---|---|---|
| Functional (Benign) | 1.07 (No Increase) | The same risk as the general population. |
| Intermediate | 1.28 (Borderline) | No statistically significant increase in risk. |
| Damaging | 4.67 (High Risk) | A substantial increase in risk. Preventive measures are needed. |
The Big Data Era in Genomic Medicine
This study provides a model not only for the PALB2 gene but for our entire genetic inheritance. In the past, when a mutation was found, answering the question of what it meant required years of follow-up of cases. Now we can test thousands of mutations simultaneously in the laboratory and map their functions.
Implications for Clinical Practice:
- Uncertainty Is Ending: We now have a clear answer for approximately 30% of our patients whose genetic test reports show a PALB2 VUS.
- Treatment Decisions: Patients with damaging missense variants should be managed as high-risk patients, just like BRCA carriers or patients with PALB2 protein loss, and assessed as candidates for PARP inhibitor treatments.
- Family Screening: This dataset will prevent false alarms when screening at-risk families (unnecessary worry caused by benign variants) and enable us to identify those truly at risk (hidden dangerous variants).
To sum up, genetic testing is not simply finding a spelling error; it is understanding how that error changes the fate of the cell. This study is a vast dictionary that lets us read that fate.
References
- Boonen RACM, et al. Site-saturation functional screens identify PALB2 missense variants associated with increased breast cancer risk. Nature Communications. 2026 Jan 19;17:775.
- Richards S, et al. Standards and guidelines for the interpretation of sequence variants. Genet Med. 2015.
- Tischkowitz M, et al. PALB2 and breast cancer: ready for clinical translation? Endocr Relat Cancer. 2020.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.